Oligonucleotide R&D

Oligonucleotide R&D 00:00 - 00:30

A Deep Dive into RNA Biology: Function and Targets of RBPs and Non-Coding RNAs

André Gerber - Professor, University of Surrey

Oligonucleotide R&D 00:30 - 01:00

Promoting efficacy and safety of oligonucleotide therapeutics through transcriptomics profiling

Nicola Guzzi - Associate Principal Scientist, AstraZeneca

Oligonucleotide R&D 01:00 - 01:30

Realzing The Potential of Long Non-Coding RNAs To Develop Transformative Medicines

Dominique Verhelle - Co-Founder & CEO, NextRNA

Oligonucleotide R&D 01:30 - 02:00

MicroRNA Targeting Regenerative Treatments for Heart Diseases

Bhawanjit Brar - CEO, Jaan Biotherapeutics

Oligonucleotide R&D 02:00 - 02:30

Exploring the Role of miR-22 in Obesity

Riccardo Panella - CSO and Scientific Founder, Resalis Therapeutics

Oligonucleotide R&D 02:30 - 03:00

Durable suppression of seizures in a mouse model of KCNT1 epilepsy with divalent small interfering RNA

Stefan McDonough, Ph.D. - Senior Vice President, Head of Neuroscience, Atalanta Tx

Oligonucleotide R&D 03:00 - 03:30

Targeting Obesity with RNAi-based Therapies

James Hamilton, MD - Vice President of Clinical Research, Arrowhead Pharmaceuticals

Oligonucleotide R&D 03:30 - 04:00

The Impact of Phosphoryl Guanidine (PN) Backbone Linkages on AIMer-mediated RNA Editing Across Cell and Tissue Types

Chandra Vargeese, PhD - Chief Technology Officer, Wave Life Science

Oligonucleotide R&D 04:00 - 04:30

The Impact of Nucleoside Analogs on the Activity of Oligonucleotides that Direct ADARs for Therapeutic RNA Editing

Peter Beal, PhD - Professor, Department of Chemistry, UC Davis

Oligonucleotide R&D 04:30 - 05:00

Recent Updates on Guanidine Bridged Nucleic Acid (GuNA) and 5′-cyclopropylene DNA (5′-CP), Demonstrating Their Potential to Improve Tolerability and Potency of Therapeutic Oligonucleotides

Ajaya Shrestha, PhD - Chemistry Group Lead, Luxna Biotech

Oligonucleotide R&D 05:00 - 05:30

Design, Synthesis, and Characterization of Novel 2ʹ-O-Substituted siRNAs for Targeting Hepatitis B Virus

Kellan Passow, PhD - Scientist II, Aligos Therapeutics

Oligonucleotide R&D 05:30 - 06:00

Progress Towards Oligonucleotide Therapeutics for Prion Disease

Sonia Henriques - Associate Professor in Biochemistry, The University of Queensland

Oligonucleotide R&D 06:00 - 06:30

Antisense Oligonucleotides for the Treatment of Neurological Disease

Holly Kordasiewicz, PhD- - SVP Research, Franchise Leader Neurology R&D, Ionis Pharmaceuticals

Oligonucleotide R&D 06:30 - 07:00

Intrathecal Delivery of Antisense Oligonucleotides for Treatment of a Genetic Form of Epilepsy

Meena PhD - SVP, Translational DMPK and Clinical Pharmacology, Stoke Therapeutics

Oligonucleotide R&D 07:00 - 07:30

Delivering the Promise of RNAi to Extra-hepatic Tissues

Punit Seth, PhD - SVP, Research, Alnylam Pharmaceuticals

Oligonucleotide R&D 07:30 - 08:00

Correcting Aberrant Splicing of UNC13A As a Treatment for People with ALS

Shila Mekhoubad, PhD - Senior Director, Biology, Trace Neuroscience

Oligonucleotide R&D 08:00 - 08:30

Extending Oligonucleotide Delivery and Gene Knockdown to Specific Cell Types in Kidney

Alfica Sehgal, PhD - Chief Scientific Officer, Judo Bio

Oligonucleotide R&D 08:30 - 09:00

FORCE(TM) Platform Enables TfR1-mediated Delivery of Therapeutics for Rare Neuromuscular Diseases

Stefano Zanotti, PhD - VP, Head of Neuromuscular Research, Dyne Therapeutics

Oligonucleotide R&D 09:00 - 09:30

Biological Research with Thiomorpholino Oligonucleotides (TMOs)

Marvin Caruthers, PhD - Distinguished Professor, Biochemistry, University of Colorado

Oligonucleotide R&D 09:30 - 10:00

Nitto Bispecific siRNA Targeting YAP1/WWTR1 As A Novel Therapeutic Agent for Liver Fibrosis

Masayuki Sugimoto, PhD - Manager, Nitto Denko Corporation

Save up to $150 - Purchase by Aug 22

Save up to $150 - Purchase by Aug 22

Oligonucleotide R&D